These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34645699)

  • 21. Preclinical diagnosis of wild-type transthyretin amyloid cardiomyopathy in a patient undergoing carpal tunnel release.
    Nakashima N; Takashio S; Morioka M; Nishi M; Hirakawa K; Hanatani S; Masuda T; Ueda M; Tsujita K
    J Cardiol Cases; 2021 Nov; 24(5):250-253. PubMed ID: 34868409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
    Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
    Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Patel RK; Ioannou A; Razvi Y; Chacko L; Venneri L; Bandera F; Knight D; Kotecha T; Martinez-Naharro A; Masi A; Porcari A; Brown J; Patel K; Manisty C; Moon J; Rowczenio D; Gilbertson JA; Sinagra G; Lachmann H; Wechalekar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
    Eur J Heart Fail; 2022 Dec; 24(12):2355-2363. PubMed ID: 36575133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
    Ruberg FL; Grogan M; Hanna M; Kelly JW; Maurer MS
    J Am Coll Cardiol; 2019 Jun; 73(22):2872-2891. PubMed ID: 31171094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
    Lane T; Fontana M; Martinez-Naharro A; Quarta CC; Whelan CJ; Petrie A; Rowczenio DM; Gilbertson JA; Hutt DF; Rezk T; Strehina SG; Caringal-Galima J; Manwani R; Sharpley FA; Wechalekar AD; Lachmann HJ; Mahmood S; Sachchithanantham S; Drage EPS; Jenner HD; McDonald R; Bertolli O; Calleja A; Hawkins PN; Gillmore JD
    Circulation; 2019 Jul; 140(1):16-26. PubMed ID: 31109193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
    Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus.
    Chander Mohan J; Dalal J; Chopra VK; Narasimhan C; Kerkar P; Oomman A; Ray Fcsi S; Sharma AR; Dougall P; Simon S; Verma Drm A; Radhakrishnan V
    Indian Heart J; 2022; 74(6):441-449. PubMed ID: 36410415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R
    Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.
    Lin W; Chattranukulchai P; Lee AP; Lin YH; Yu WC; Liew HB; Oomman A
    Clin Cardiol; 2022 Sep; 45(9):898-907. PubMed ID: 35795903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
    Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
    ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Transthyretin amyloid cardiomyopathy].
    Hansen PR; Krakauer M
    Ugeskr Laeger; 2020 Feb; 182(6):. PubMed ID: 32089152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
    Nativi-Nicolau JN; Karam C; Khella S; Maurer MS
    Heart Fail Rev; 2022 May; 27(3):785-793. PubMed ID: 33609196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of transthyretin cardiac amyloidosis in elderly patients diagnosed with heart failure.
    Jaramillo-Hidalgo J; Quezada-Feijoó M; Ramos M; Toro R; Gómez-Pavón J; Ayala-Muñoz R
    Rev Esp Geriatr Gerontol; 2023; 58(1):8-14. PubMed ID: 36404188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetics of cardiac amyloidosis.
    Arno S; Cowger J
    Heart Fail Rev; 2022 Sep; 27(5):1485-1492. PubMed ID: 34518987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.